2004

1. Lorenzo AJ, Samuelson ML, Docimo SG, Baker LA, Lotan Y: Cost analysis of laparoscopic versus open orchiopexy in the management of unilateral nonpalpable testicles. J Urol. 172(2): 712-716, 2004.
2. Dravis C, Yokoyama N, Chumley MJ, Cowan  CA  , Silvany RE, Shay J, Baker LA, Henkemeyer M: Bidirectional signaling mediated by ephrin-B2 and EphB2 controls urorectal development. Dev Biol. 271(2): 272-290, 2004.
3. Cowan CA, Yokoyama N, Saxena A, Chumley MJ, Silvany RE, Baker LA, Srivastava D, Henkemeyer M: Ephrin-B2 reverse signaling is required for an axon pathfinding and cardiac valve formation but not early vascular development. Dev Biol. 271(2): 263-271, 2004.
4. Karam, JA and Baker, LA:   True Hermaphrodite.   New Engl J Med, 350:393, 2004.
5. Lorenzo AJ, Samuelson ML, Docimo SG, Baker LA, Lotan Y:   Cost analysis of laparoscopic versus open orchiopexy in the management of unilateral nonpalpable testicles.   J Urol., 172(2):712-716, 2004.
6. Benaim EA, Karam JA, Saboorian MH, Roehrborn CG, McConnell JD, Lin V: The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate, 60(4): 310-316, 2004.
7. Shulman MJ, Benaim EA: The natural history of androgen independent prostate cancer. J. Urol., 172(1): 141-145, 2004.
8. Shulman MJ, Karam JA, Benaim EA: Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology, 63(4): 732-736, 2004.
9. Karam JA, Shulman MJ, Benaim EA: Impact of training level of urology residents on the detection of prostate cancer on TRUS biopsy. Prostate Cancer Prostatic Dis., 7(1): 38-40, 2004.
10. Margulis V, Matsumoto ED, Lindberg G, Tunc L, Taylor G, Sagalowsky AI, Cadeddu JA: Acute histologic effects of temperature-based radiofrequency ablation on renal tumor pathologic interpretation. Urology 64(4): 660-663, 2004.
11. Johnson DB, Kondraske GV, Wilhelm DM, Jacomides L, Ogan K, Pearle MS, and Cadeddu JA. Assessment of basic human performance resources predicts performance of virtual ureterorenoscopy.   J Urol 171:80, 2004.
12. Jacomides L, Ogan K, Cadeddu JA and Pearle MS.   The utility of a virtual reality simulator for ureteroscopy training. J Urol 171:320, 2004.
13. Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, McConnell JD, Holmes MN, and Roehrborn CG. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy.   J Urol 171:1122, 2004.
14. Johnson DB, Cadeddu JA: Radiofrequency ablation of small renal tumors. Expert Rev Anticancer Ther. 4(1): 77-83, 2004.
15. Lotan Y, Gettman  MT  , Lindberg G, Napper CA, Hoopman J, Pearle MS, and Cadeddu JA.  Laparoscopic partial nephrectomy using holmium laser in a porcine model.  JSLS 8:51, 2004.
16. Lotan Y, Duchene DA, Cadeddu JA, Sagalowsky AI, and Koeneman  KS  .  Changing management of organ confined renal masses: The UT Southwestern Program. J Endourol 18:263, 2004.
17. Taylor, GD, Johnson DB, Hogg DC, and Cadeddu JA. Development of a renal tumor-mimic model for learning minimally invasive nephron-sparing surgical techniques. J Urol 172:382, 2004.
18. Lotan Y, Shariat SF, Khoddami SM, Koeneman  KS  , Cadeddu JA, Sagalowsky AI, McConnell JD, and Roehrborn CG. The percent of biopsy cores positive for cancer is a predictor of advanced pathologic stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol 171:2209, 2004.
19. Taylor GD, Cadeddu JA: Applications of laparoscopic surgery in urology: impact on patient care. Med Clin North Am. 88(2): 519-538, 2004.
20. Matsumoto ED, Watumull L, Johnson DB, Ogan K, Taylor GD, Josephs S and Cadeddu JA. The radiographic evolution of radiofrequency ablated renal tumors. J Urol 172:45, 2004.
21. Ogan K, Jacomides L, Shulman MJ, Roehrborn CG, Cadeddu JA and Pearle MS. Virtual ureteroscopy predicts ureteroscopic proficiency of medical students on a cadaver. J Urol 172:667, 2004.
22. Duchene DA, Jacomides L, Ogan K, Lindberg G, Johnson DB, Pearle MS, and Cadeddu JA.   Ureteral replacement using small intestine submucosa and a collagen inhibitor in a porcine model.   J Endourol 18:507, 2004.
23. Lotan Y, Cadeddu JA, and Gettman MT. The new economics of radical prostatectomy: cost-comparison of open, laparoscopic, and robot-assisted techniques. J Urol 172:1431, 2004.
24. Johnson DB, Solomon SB, Shingleton WB, Moon TD, Su LM, Nakada SY, Jarrett TW, Matsumoto ED, and Cadeddu JA.   Defining the complications of cryoablation and radiofrequency ablation of small renal tumors: a multi-institutional review. J Urol 172:874, 2004.
25. Huang CL, Cheng JC, Liao CH, Stern A, Hsieh JT, Wang CH, Hsu HL, Tseng CP: Disabled-2 is a negative regulator of integrin alpha(Iib) beta(3)-mediated fibrinogen adhesion and cell signaling. J Biol Chem. 279(40): 42279-42289, 2004
26. Okegawa T, Pong RC, Li Y, Hsieh JT: The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Po. 51(2): 445-457, 2004.
27. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, Chen H, Hsieh JT, Gazdar AF, Shimizu N: Aberrant promoter methylation in human dab2 interactive protein (hdab2ip) gene in breast cancer. Clin Cancer Res., 10: 2082-2089, 2004.
28. Defreitas  GA  , Zimmern PE , Lemack GE, Shariat SF: Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology, 64(4): 675-679, 2004.
29. Lemack GE: Porcine dermal sling versus tension-free vaginal tape. Curr Urol Rep. 5(5): 372-373, 2004.
30. Lemack GE: Randomized surgical trials for the treatment of stress urinary incontinence. Curr Urol Rep. 5(5): 371, 2004.
31. Lemack GE: Comparison between a modified burch procedure and a suburethral sling. Curr Urol Rep. 5(5): 371-372, 2004.
32. Gupta A, Defreitas G, Lemack GE: The reproducibility of uroydnamic findings in healthy female volunteers: results of repeated studies in the same setting and after short-term follow-up. Neurourol Urodyn., 23(4):311-316, 2004.
33. Lotan Y, Cadeddu JA, Gettman  MT  : The new economics of radical prostatectomy: evaluation of laparoscopic and robot-assisted techniques.   J Urol., 172(4, Part 1 Of 2):1431-1435, 2004.
34. Lorenzo AJ, Samuelson ML, Docimo SG, Baker LA, Lotan Y:   Cost analysis of laparoscopic versus open orchiopexy in the management of unilateral nonpalpable testicles.   J Urol., 172(2):712-716, 2004.
35. Lotan R, Lotan Y: Retinoic acid receptor beta2 hypermethylation: implications for prostate cancer detection, prevention, and therapy. Clin Cancer Res 10(12 Pt 1): 3935-3936, 2004.
36. Khoddami SM, Shariat SF, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI, Roehrborn CG, Koeneman  KS  :  Predictive value of primary gleason pattern 4 in patients with gleason score 7 tumours treated with radical prostatectomy.  BJU Int. 2004 Jul;94(1):42-46, 2004.
37. Lotan Y, Shariat SF, Khoddami SM, Saboorian H, Koeneman  KS  , Cadeddu JA, Sagalowsky AI, McConnell JD, Roehrborn CG.: The percent of biopsy cores positive for cancer is a predictor of advanced pathologic stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol.,  171(6, Part 1 Of 2):2209-2214, 2004.
38. Lotan Y, Duchene DA, Cadeddu JA, Sagalowsky AI, Koeneman  KS  : Changing management of  organ confined renal masses: A new treatment algorithm. J Endourol., 18(3):263-268, 2004.
39. Lotan Y, Gettman  MT  , Lindberg G, Napper CA, Hoopman J, Pearle MS, Cadeddu JA.: Laparoscopic partial nephrectomy using holmium laser in a porcine model. JSLS., 8(1):51-55, 2004.
40. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R.: Survivin expression is associated with features of biologically aggressive prostate cancer. Cancer., 100(4):751-757, 2004.
41. Pak CY, Adams-Huet B, Poindexter JR, Pearle MS, Peterson RD  , Moe OW: Relative effect of urinary calcium and oxalate on saturation of calcium oxalate. Kidney Int. 66(5): 2032-2037, 2004.
42. Traxer O, Pasqui F, Gattegno B, Pearle MS: Technique and complications of transurethral surgery for bladder tumours. BJU Int., 94(4): 492-496, 2004.
43. Duchene DA, Jacomides L, Ogan K, Lindberg G, Johnson DB, Pearle MS, and Cadeddu JA.   Ureteral replacement using small intestine submucosa and a collagen inhibitor in a porcine model.   J Endourol 18:507-511, 2004.
44. Ogan K, Jacomides L, Shulman MJ, Roehrborn CG, Cadeddu JA, Pearle MS: Virtual ureteroscopy predicts ureteroscopic proficiency of medical students on a cadaver. J Urol., 172: 667-671, 2004.
45. Lallas CD, Pearle MS, Leveillee RJ, Lingeman JE, Schwope JP, Pietrow PK, Preminger GM, Auge BK: Internet-based multi-institutional clinical research: a convenient and secure option. J Urol., 171: 1880-1885, 2004.
46. Johnson DB, Pearle MS: Complications of ureteroscopy. Urol Clin North Am., 31(1): 157-171, 2004.
47. Lotan Y, Gettman  MT  , Lindberg G, Napper CA, Hoopman J, Pearle MS, and Cadeddu JA: Laparoscopic partial nephrectomy using holmium laser in a porcine model. JSLS, 8:51-55, 2004.
48. Jacomides L, Ogan K, Cadeddu JA, and Pearle MS: Use of a virtual reality simulator for ureteroscopy training. J Urol., 171: 320-323, 2004.
49. Johnson DB, Kondraske GV, Wilhelm DM, Jacomides L, Ogan K, Pearle MS, Cadeddu JA: Assessment of basic human performance resources predicts the performance of virtual ureterorenoscopy. J Urol., 171: 80-84, 2004.
50. Boyle P, Robertson C, Lowe F, and Roehrborn C: Updated meta-analysis of clinical trials of serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. 93: 751-756, 2004.
51. Claus G. Roehrborn and Debra A. Schwinn: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J. Urol., 171:1029-1035, 2004.
52. Shahrokh F. Shariat, Seyed M. Khoddami, Hossein Saboorian, Kenneth S. Koeneman, Arthur I. Sagalowsky, Jeffrey A. Cadeddu, John D. McConnell, Marissa N. Holmes and Claus G. Roehrborn: Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol., 171: 1122-1127, 2004.
53. Claus G. Roehrborn, Reginald Bruskewitz, J. Curtis Nickel, John D. McConnell, Brian Saltzman, Marc C. Gittelman, Gholem H. Malek, James E. Gottesman, Shilaja Suryawanshi, Jennifer Drisko, Alan Meehan, and Joanne Waldstreicher for the Proscar Long-Term Efficacy and Safety Study Group: Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J. Urol., 171: 1194-1198, 2004.
54. Andrew J. Stephenson, Shahrokh F. Shariat, Michael J. Zelefsky, Michael W. Kattan, E. Brian Butler, Bin S. Teh,   Eric A. Klein, Patrick A. Kupelian, Claus G. Roehrborn, David A. Pistenmaa, Heather D. Pacholke, Stanley L. Liauw, Matthew S. Katz, Steven A. Leibel, Peter T. Scardino and Kevin M. Slawin: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. American Medical Association (Reprinted JAMA), 1325-1332, 2004.
55. C. G. Roehrborn: The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU International, 93(1): 21-26, 2004.
56. G Bartsch, JM Fitzpatrick, JA Schalken, J Isaacs, J Nordling and CG Roehrborn: Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU International, 93(1): 27-29, 2004.
57. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittelman M, Morrill B, and Wolford ET: Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63: 709-715, 2004.
58. Bruce J. Trock, Michelle Brotzman, William J. Utz, Roland R. Ugarte, Steven A. Kaplan, Thayne R. Larson, Michael L. Blute, Claus G. Roehrborn, and Alan W. Partin: Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia: results at three months through four years. Urology, 63: 716-721, 2004
59. David G. Bostwick, Jungi Qian, Francisco Civantos, Claus G. Roehrborn and Rodolfo Montironi: Does finasteride alter the pathology of the prostate and cancer grading? Clinical Prostate Cancer, 2(4): 228-235, 2004.
60. Yair Lotan, Sharokh F. Shariat, Seyed M. Khoddami, Hossein Saboorian, Kenneth S. Koeneman, Jeffrey A. Cadeddu, Arthur I. Sagalowsky, John D. McConnell and Claus G. Roehrborn: The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol., 171: 2209-2214, 2004.
61. Brian Hill, William Belville, Reginald Bruskewitz, Muta Issa, Ramon Perez-Marrero, Claus Roehrborn, Martha Terris and Michael Naslund: Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year-results of a prospective, randomized, multicenter clinical trial. J Urol, 171: 2336-2340, 2004.
62. Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M: 5-alpha redutase inhibition provides superior benefits to alpha blockade by preventing aur and bph-related surgery. European Urology 45: 620-626; discussion 626-627, 2004.
63. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer, 100: 751-757, 2004.
64. Amit Gupta and Claus G. Roehrborn: Verification and incorporation biases in studies assessing screening tests: prostate-specific antigen as an example. Urology, 64: 106-111, 2004.
65. Benaim EA, Karam JA, Saboorian MH, Roehrborn CG, McConnell JD, Lin V: The effect of combined androgen ablation on the expression of alpha (1A)-adrenergic receptor in the human prostate. Prostate, 60: 310-316, 2004.
66. Ogan K, Jacomides L, Shulman MJ, Roehrborn CG, Cadeddu JA, Pearle MS: Virtual ureteroscopy predicts ureteroscopic proficiency of medical students on a cadaver. J Urol. 172: 667-671, 2004.
67. Khoddami SM, Shariat SF, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI, Roehrborn CG, Koeneman  KS  : Predictive value of primary gleason pattern 4 in patients with gleason score 7 tumours treated with radical prostatectomy. BJU Int., 94: 42-46, 2004.
68. GL Andriole, C Roehrborn, C Schulman, KM Slawin, M Somerville, and RS Rittmaster: Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology, 64: 537-543, 2004.
69. Gerald Andriole, Nicholas Bruchovsky, Leland WK Chung, Alvin M. Matsumoto, Roger Rittmaster, Claus Roehrborn, David Russell and Donald Tindall: Dihydrotestosterone and the prostate: the scientific rationale for 5-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol., 172: 1399-1403, 2004.
70. Frans Debruyne, Jack Barkin, Peter van Erps, Mario Reis, Teuvo LJ Tammela and Claus Roehrborn on behalf of the ARIA 3001, 3002 and ARIA 3003 Study Investigators: Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. European Urology, 46: 488-495, 2004.
71. Margulis V, Matsumoto ED, Lindberg G, Tunc L, Taylor G, Sagalowsky AI, Cadeddu JA: Acute histologic effects of temperature-based radiofrequency ablation on renal tumor pathologic interpretation. Urology 64(4): 660-663, 2004.
72. Lotan Y, Duchene DA, Cadeddu JA, Sagalowsky AI, Koeneman  KS  : Changing management of organ-confined renal masses. J Endourol., 18(3): 263-268, 2004.
73. Khoddami SM, Shariat SF, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI, Roehrborn CG, Koeneman  KS  : Predictive value of primary gleason pattern 4 in patients with gleason score 7 tumours treated with radical prostatectomy. BJU Int., 94: 42-46, 2004.
74. Yair Lotan, Sharokh F. Shariat, Seyed M. Khoddami, Hossein Saboorian, Kenneth S. Koeneman, Jeffrey A. Cadeddu, Arthur I. Sagalowsky, John D. McConnell and Claus G. Roehrborn: The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol., 171: 2209-2214, 2004.
75. Shariat SF, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI: Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. European Urology, 45(3): 304-313; author reply 313, 2004.
76. Shahrokh F. Shariat, Seyed M. Khoddami, Hossein Saboorian, Kenneth S. Koeneman, Arthur I. Sagalowsky, Jeffrey A. Cadeddu, John D. McConnell, Marissa N. Holmes and Claus G. Roehrborn: Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol., 171: 1122-1127, 2004.
77. Snodgrass WT, Adams R: Initial urologic management of myelomeningocele. Urol Clin North Am, 31(3): 427-434, viii. Review, 2004.
78. Nguyen MT, Snodgrass WT: Tubularized incised plate hypospadias reoperation. J Urol, 171(6, Pt 1): 2404-2406, discussion 2406, 2004.
79. Nguyen MT, Snodgrass WT, Zaontz MR: Effect of urethral plate characteristics on tabularized incised plate urethroplasty. J Urol, 171(3): 1260-1262; discussion 1262, 2004.
80. Snodgrass WT: Consultation with the specialist: hypospadias. Pediatr Rev, 25(2): 63-67. Review, 2004.
81. Snodgrass WT: Obstruction of a dysmorphic ureter following dextranomer/hyaluronic acid copolymer. J Urol, 171(1): 395-396, 2004.
82. Husmann DA, Snodgrass WT, Koyle MA, Furness PD 3rd, Kropp BP, Cheng EY, Kaplan WE, Kramer SA: Ureterocystoplasty: indications for a successful augmentation. J Urol, 171(1): 376-380. Erratum in J Urol 131(3): 1247, 2004.
83. Davies MC, Creighton SM, Wilcox DT: Long-term outcomes of anorectal malformations. Pediatr Surg Int. 20(8): 567-572, 2004.
84. McHoney M, Ransley PG, Duffy P, Wilcox DT, Spitz L: Cloacal exstrophy: morbidity associated with abnormalities of the gastrointestinal tract and spine. J. Pediatr Surg. 39(8): 1209-1213, 2004.
85. Sau I, Warne SA, Wilcox DT: Unusual variety of posterior cloaca. J Urol. 171(3): 1291, 2004.
86. Zimmern  PE  : Reply by the authors. Urology, 64(4): 680-681, 2004.
87. Defreitas  GA  , Zimmern PE , Lemack GE, Shariat SF: Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology, 64(4): 675-679, 2004.
88. Poon CI, Zimmern  PE  : Role of three-dimensional ultrasound in assessment of women undergoing urethral bulking agent therapy. Current Opin Obstet Gynecol 16(5):411-417, 2004.
89. Margulis V, Defreitas G, Zimmern  PE  : Urinary retention after tension-free vaginal tape procedure: from incision to excision… to complete urethrolysis. Urology 64(3): 590, 2004.

Return to Basic Science Research

For more information about the Department of Urology, contact:

Phone: 214-648-4765, FAX: 214-648-4789

Mailing Address: 5323 Harry Hines Blvd. , J8.148, Dallas , TX 75390-9110